Clinical Trial Update: Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a combination of carfilzomib, thalidomide, and dexamethasone in relapsed and/or refractory multiple myeloma; current status is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Carfilzomib (carfilzomib)
• DEXAMETHASONE (Dexamethasone)
• Thalidomide (thalidomide)

Snippet

Sponsor: National University Hospital, Singapore | Conditions: Relapsed and/or Refractory Multiple Myeloma | Phase 2 | Status: UNKNOWN